Eisai Threatens To End Pfizer Alliance On Aricept Following Wyeth Acquisition
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai announced that it "has the right" to terminate a product development and business alliance agreement for its Alzheimer's treatment Aricept (donepezil) if Pfizer acquires Wyeth
You may also be interested in...
Pfizer and Eisai Will Continue Aricept Deal, But Add Lyrica To The Agreement
A potential sticking point in Pfizer's acquisition of Wyeth has been resolved - the big drug maker and Eisai have agreed to continue co-promoting Aricept (donepezil) in the U.S., Europe and Japan. However, Eisai will regain full Japanese rights to the Alzheimer's blockbuster at the end of 2012, while the rest of the collaboration will remain in place until 2022
Pfizer and Eisai Will Continue Aricept Deal, But Add Lyrica To The Agreement
A potential sticking point in Pfizer's acquisition of Wyeth has been resolved - the big drug maker and Eisai have agreed to continue co-promoting Aricept (donepezil) in the U.S., Europe and Japan. However, Eisai will regain full Japanese rights to the Alzheimer's blockbuster at the end of 2012, while the rest of the collaboration will remain in place until 2022
Eisai To Reinforce Oncology R&D, Sales To Achieve 17% Income Rise
TOKYO - Quadrupling profits in the business year from the preceding year and forecasting a solid 17.5 percent rise in the current year, Eisai Co., the fourth-largest Japanese pharma and the only one reporting profit among the four, said it will further reinforce its oncology drug development and sales while accelerating global distribution of Alzheimer's treatment Aricept